Abstract
Although the COVID-19 pandemic has left no country untouched there has been limited research to understand clinical and immunological responses in African populations. Here we comprehensively characterise patients hospitalised with suspected or confirmed COVID-19, and healthy community controls. PCR-confirmed COVID-19 participants were more likely to receive dexamethasone and a beta-lactam antibiotic, and survive to hospital discharge than PCR-/IgG+ and PCR-/IgG-participants. PCR-/IgG+ participants exhibited a nasal and systemic cytokine signature analogous to PCR-confirmed COVID-19 participants, but increased propensity for Staphylococcus aureus and Streptococcus pneumoniae colonisation. We did not find evidence that HIV co-infection in COVID-19 participants was associated with mortality or altered cytokine responses. The nasal immune signature in PCR-/IgG+ and PCR-confirmed COVID-19 participants was distinct and predominated by chemokines and neutrophils. In addition, PCR-/IgG+ individuals with high COVID-19 clinical suspicion had inflammatory profiles analogous to PCR-confirmed disease and potentially represent a target population for COVID-19 treatment strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors thank all study participants and the staff of the Queen Elizabeth Central Hospital (QECH) for their support and co-operation during the study. This work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome [220757/Z/20/Z] (BM). Further support was provided by Wellcome [211433/Z/18/Z] (SBG) and National Institute for Health Research (NIHR) [16/136/46] (KCJ). KCJ is supported by an MRC African Research Leader award [MR/T008822/1]. JR is supported by a Wellcome Trust Career Development Fellowship [211098/Z/18/Z]. KB is supported by a NIH K-award (TW010853). KJ is supported by a Wellcome International Training Fellowship [201945/Z/16/Z]. A Wellcome Strategic award number 206545/Z/17/Z supports the Malawi-Liverpool-Wellcome Trust Clinical Research Programme (SBG). The views expressed are those of the authors and not necessarily those of the UK NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Malawi National Health Science Research Committee (NHSRC, 20/02/2518 and 19/08/2246) and Liverpool School of Tropical Medicine (study sponsor) Research Ethics Committee (LSTM REC, 20/026 and 19/017)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Clinical data has been made available to the ISARIC database. Requests for immunological data will be considered on a case by case basis according to protocolised Malawi-Liverpool Wellcome Trust Clinical Research Programme processes
